Analysts at StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO – Get Free Report) in a note issued to investors on Sunday. The brokerage set a “hold” rating on the stock.
EKSO has been the subject of a number of other research reports. Lake Street Capital decreased their target price on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a research report on Tuesday, October 29th. HC Wainwright lowered their target price on Ekso Bionics from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Tuesday, October 29th.
Check Out Our Latest Research Report on EKSO
Ekso Bionics Price Performance
Ekso Bionics (NASDAQ:EKSO – Get Free Report) last announced its earnings results on Monday, October 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. The firm had revenue of $4.13 million during the quarter, compared to analyst estimates of $6.00 million. During the same period in the prior year, the business posted ($0.24) EPS. Equities analysts forecast that Ekso Bionics will post -0.48 EPS for the current fiscal year.
About Ekso Bionics
Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.
Further Reading
- Five stocks we like better than Ekso Bionics
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- 3 Must-Hold Stocks with Double-Digit Upside for 2025
- Business Services Stocks Investing
- Micron: Why Now Is the Time to Be Brave
- How to Calculate Options Profits
- 3 Stocks That Wall Street Insiders Can’t Stop Buying
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.